A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease

Launched by VERVE THERAPEUTICS, INC. · Dec 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called VERVE-102 for patients with a genetic condition known as heterozygous familial hypercholesterolemia (HeFH) or those with early heart disease due to high cholesterol. The goal is to see if VERVE-102 is safe and effective at lowering cholesterol levels, particularly a type called LDL cholesterol, which is often referred to as "bad" cholesterol. This treatment works by targeting a specific gene in the liver that affects cholesterol levels.

To participate in this study, you must have been diagnosed with HeFH or premature coronary artery disease. The trial is open to both men and women, but women must not be able to have children. Unfortunately, those with a more severe form of the condition called homozygous familial hypercholesterolemia or those with certain liver issues cannot join. If you qualify and choose to participate, you’ll receive the treatment and will be monitored closely to ensure your safety. This study is currently looking for volunteers, so if you or someone you know fits the criteria, it could be a great opportunity to contribute to important research in heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of HeFH or premature CAD
• • Females of non-childbearing potential or males
• Exclusion Criteria:
• • Homozygous familial hypercholesterolemia
• • Active or history of chronic liver disease
• • Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
• • Clinically significant or abnormal laboratory values as defined by the protocol